John P. Sharp
2019 - PhaseBio Pharmaceuticals
In 2019, John P. Sharp earned a total compensation of $747.9K as Chief Financial Officer at PhaseBio Pharmaceuticals, a 61% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $182,325 |
|---|---|
| Option Awards | $199,350 |
| Salary | $356,283 |
| Other | $9,905 |
| Total | $747,863 |
Sharp received $356.3K in salary, accounting for 48% of the total pay in 2019.
Sharp also received $182.3K in non-equity incentive plan, $199.4K in option awards and $9.9K in other compensation.
Rankings
In 2019, John P. Sharp's compensation ranked 10,471st out of 13,971 executives tracked by ExecPay. In other words, Sharp earned more than 25.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,471 out of 13,971 | 25th |
Division Manufacturing | 4,233 out of 5,701 | 26th |
Major group Chemicals And Allied Products | 1,639 out of 2,200 | 26th |
Industry group Drugs | 1,405 out of 1,886 | 26th |
Industry Pharmaceutical Preparations | 1,042 out of 1,398 | 26th |
Source: SEC filing on April 24, 2020.
Sharp's colleagues
We found two more compensation records of executives who worked with John P. Sharp at PhaseBio Pharmaceuticals in 2019.